News Releases

Month Year

Su	Mo	Tu	We	Th	Fr	Sa
25	26	27	28	29	30	1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30	31	1	2	3	4	5

Cancel Go

Month Year

Su	Mo	Tu	We	Th	Fr	Sa
25	26	27	28	29	30	1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30	31	1	2	3	4	5

Cancel Go

Email Alerts

Year All Years 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 Keywords Go

Advanced Search

Keywords

  Search Headlines Only

From

To

Asset Types

 Photos  Video  Audio  Documents  Events  Standard

 Basic Search

• Dec 21, 2004

  Insmed Incorporated Released the Following Statement in Response to a Press Release Made Yesterday by Tercica, Inc.
• Nov 9, 2004

  Insmed Announces Expansion of Patent Portfolio in the Treatment of Diabetes; New European Patent Granted for SomatoKine
• Nov 8, 2004

  Insmed Raises Approximately $8.7 Million in Direct Placement of Common Stock
• Nov 8, 2004

  Insmed Incorporated Reports Financial Results for Third Quarter and First Nine-Months of 2004
• Oct 26, 2004

  Insmed to Present at Rodman and Renshaw Healthcare Conference October 28, 2004; Presentation to Be Webcast Live
• Oct 21, 2004

  Insmed and Tzamal Pharma Announce Agreement for the Promotion and Distribution of SomatoKine in Middle Eastern Territories
• Oct 19, 2004

  Insmed Announces Initiation of Clinical Study of Small Molecule IGF-IR Tyrosine Kinase Inhibitor
• Sep 13, 2004

  Insmed Reports Results from Nine Months of SomatoKine Therapy for a Patient with Extreme Insulin Resistance at the 43rd Meeting of the European Society of Pediatric Endocrinology
• Sep 8, 2004

  Insmed Initiates Phase I Clinical Study for Novel Anti-Tumor Protein
• Aug 17, 2004

  Insmed Requests Halt of Trading of Its Common Stock on the Berlin-Bremen Stock Exchange; Company Also Initiates Short Selling Audit
• Jul 28, 2004

  Insmed Incorporated Reports Financial Results for Second Quarter and First Half of 2004
• Jul 21, 2004

  Insmed to Report Second Quarter Financial Results;Wednesday, July 28
• Jul 20, 2004

  Insmed Reports Update on Pivotal Clinical Trial with SomatoKine: Statistically Significant Increase in Growth Rate Observed at Six Months
• Jul 19, 2004

  Insmed Receives Authorization for Reimbursement for SomatoKine Named Patient Program from France and Italy; Newly Appointed Chief Business Officer Expands the Named Patient Program
• Jul 19, 2004

  Insmed Announces Two Independent Presentations at the National Cancer Institutes 12th Annual Meeting of SPORE
• May 13, 2004

  Breast Cancer Center of Excellence Awarded $10 Million Department of Defense Grant; rhIGFBP-3 Selected as a Candidate Agent in Clinical Trials
• May 11, 2004

  Insmed to Present at Rodman and Renshaw Healthcare Conference May 13, 2004; Presentation to Be Webcast Live
• May 5, 2004

  Insmed Incorporated Reports Financial Results for First Quarter of 2004
• Apr 29, 2004

  Insmed Incorporated to Webcast First Quarter Earnings Conference Call; Thursday, May 6, at 11:00 a.m. ET - 10:00 a.m. CT
• Apr 14, 2004

  Insmed Acquires Manufacturing Facility from Baxter International
• Mar 23, 2004

  Insmed to Present at Wells Fargo Securities Healthcare Conference
• Mar 23, 2004

  Insmed to Present at Wells Fargo Securities Healthcare Conference; Presentation to Be Webcast Live
• Feb 11, 2004

  Insmed Incorporated Reports Improved Financial Results for Fourth Quarter 2003 and Twelve-Months Ended December 31, 2003
• Feb 4, 2004

  Insmed Inc. to Webcast Fourth Quarter Earnings Conference Call; Wednesday, February 11, at 11:00 a.m. ET - 10:00 a.m. CT
• Jan 26, 2004

  Insmed Obtains Patent Rights for Extreme Insulin Resistance From Fujisawa

Show 5102550100 per page

Stay In The Loop

Want to stay up to date on our news, events, and filings? Set up your
email alerts.

Sign Up

View the latest Insmed Investor Presentation

Download